• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The invention provides synthetic peptides which are extremely potent in stimulating the release of pituitary GH in animals, including humans, which have resistance to enzymatic degradation in the body, and which have the sequence: (B)R1-R2-R3-Ala-Ile-Phe-Thr-R8-Ser-(Q1)R10-Arg-R12-(Q2)R13-Leu-R15-Gln -Leu-R18 (Q3)Ala-Arg-R21-(Q4)R22-Leu-R24-R25-Ile-R27-R28-Arg-Gln-Gln-Gly-Glu-R3 4-Asn-Gln- Glu-R38-R39-R40-Arg-R42-R43-R44 wherein R1 is Tyr, D-Tyr, Met, Phe, D-Phe, pCl-Phe, Leu, His or D-His; B is H, C<a>Me, N<a>Me, desamino, Ac or For; R2 is Ala, D-Ala, NMA or D-NMA; R3 is Asp or D-Asp; R8 is Ser, Asn, Lys, Arg, Asp or Gln; R10 is Tyr, D-Tyr or Phe; R12 is Arg or Lys; R13 is Ile, Val, Leu or Ala; R15 is Gly or Ala; R18 is Ser or Tyr; R21 is Lys, D-LyS, Arg or D-Arg; R22 is Leu, Ile, Ala or Val; R24 is Gln or His; R25 is Asp or Glu; R27 is Met, D-Met, Ala, Nle, Ile, Leu, Nva or Val; R28 is Asn or Ser; R34 is Ser or Arg; R38 is Arg or Gln; R39 is Gly or Arg; R40 is Ala or Ser; R42 is Phe, Ala or Val; R43 is Asn or Arg; R44 is a natural amino acid; Q1-Q4 are either H or C<a>Me, provided however that any or all of the residues between R30 and R44, inclusive, may be deleted, and provided also that at least one of Q1-Q4 is C<a>Me and/or R8 is Lys or Arg and/or R21 is D-Lys or D-Arg. These peptides as well as their nontoxic salts may also be used diagnostically.
    公开号:SU1598881A3
    申请号:SU884355674
    申请日:1988-05-16
    公开日:1990-10-07
    发明作者:Эдуард Фредерик Ривьер Джин；Волкер Вейл-Младший Вили；Лаура Ривьер Катрин
    申请人:Дзе Солк Институт Фор Биолоджикал Стадиз (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing peptides — new biologically active compounds that can be used in human and veterinary medicine.
    The purpose of the invention is to obtain chemically by new peptides that promote the growth of the growth hormone by the pituitary gland, more active, less toxic and more accessible compounds.
    The synthesis of peptides is controlled by a solid phase method.
    In the description text, the following abbreviations are used: MBGA - p-methyl benzhydrylamine resin OBzl - benzyl; Hap - xanthyl; Tos - tosil; 2-chlorobenzyloxycarbonyl; lev - 2,6-dihporbenzyl, Z - benzyloxycarbonyl; Voe - tre- . Butyloxy-carbonyl-NOV T - 1-hydroxybenzotriazole, DMF - dimethylformamide / TFA - trifluoroacetic acid,
    Example 1. Peptide Synthesis (Tyr, Asp ", Ala, hGRF (1-29) -NH2 Formula: N MeTyr-Ala- -Asp-Ala-Ile-Phe-Tyr-Asp-Ser-Tyr- -Arg-Lys- Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Ne-Asn-Arg-NH2 is performed step by step in a Beckman 990 peptide synthesizer on a MBGN resin. Binding (Tos) to this resin results in replacement of approximately 0.35 mmol Arg by 1 g of resin, the initial resin is taken in an amount of 2 g.
    After deblocking and neutralization, the peptide chain is incrementally expanded on the resin. All solvents used are thoroughly degassed by sparging with an inert gas, such as helium or nitrogen, to ensure the absence of oxygen, which can lead to an undesirable oxidation of the sulfur of the meth residue.
    Preferably released according to schedule A: Schedule A
    Reagent Mixing time, min 60% TFA / 2%
    ethanedithiol10 60% TFA / 2%
    ethandithiol 15 IPA / P. ethanediol0, 5 EtjN (10%). in CHjCl 0.5 MeOH 0.5 EtaN (10%)
    v, 0.5
    Meon (twice) 0.5.
    CH-iCli (twice) 0.5
    The connection is preferably carried out according to schedule B.
    . Graphics We're making a mix1598881
    Boc-amino acid MeOH - (twice) 5 CHjCl2 (two times Reactant DCC1
    vani min
    Dy)
    ACgO (3M) in
    , 10 Meon
    CHjCl (twice) From 1 to 2 mmol of amino acid in chl. 15 used per g 1 eq. 1.0 mol ph in methyl chloride When a Boc is bound, a mixture of 20 methylene is used. Ben is used as a defensive group by Bo Ser and Tug. Aminogram I block Hap (XA 25 uses a DCC-compliant. Compound ester (ONp) Must activate Asn or 3Q Boc-Asn (ONp) for an activator component) overnight using benzotriazole in 50 formamide and methyl case. H, H - dicyclic acid (DCC) did not add sicarbonyl (ZS1-g); as a protective chain cf.To use guanidine functional nitrogen His, and O is a hydroxyl Arg. Phenol hydrate of 2,6-dichlorobenzyl tse.- get 45 the following composition -Ala-Asp (X3) -Ala-Il -Asp (X3) -Ser (X,) -Ty-Lys (X p -Val-Leu-Al -Ser (X) -Ala-Arg (X
    -Leu-Gln (X) -Asp (X -Arg (X) -Xj,
    where X j means DCB Xan; Xf - Tos-, X-carrier or NH-MBGA can be partially or 55 under the action of TFA, releasing the alpha group. Received 6, resin.
    50-90 0.5
    Boc-amino acid MeOH - (twice) 5 CHjCl2 (two times 0, 5
    15.0 0.5 0.5
    Dy)
    ACgO (3M) in
    , 10 Meon
    CHjCl (twice) 0.5. Between 1 and 2 mmol of the Boc-protected amino acid in methylene chloride .15 is used per gram of resin, together with 1 eq. 1.0 molar solution of DCC1 in methylene chloride for 2 hours. When bound to Boc-Arg (Tos). use a mixture of 50% DMF and chlorine methylene. Benzyl ether is used as a hydroxyl protecting group of the side chain for Ser and Tug. The amino group of Asn or Gin I is blocked with Hap (xanthine) when 25 use DCC binding as preferred. The para-nitrophenyl ester (ONp) can also be used to activate the carboxyl component Asn or Gin and, for example, 3Q Boc-Asn (ONp) can be bound overnight using 1 eq. 1-hydroxybenzotriazole in a 50% mixture of dimethylformamide and methylene chloride, in this case. H, H -dicyclohexylcarbodiimide (DCC) is not added. 2-chlorobenzyloxycarbonyl (3S1-g); used as a protecting group Lys side chain. Tos is used to block the guanidine function of Arg and His imidazole nitrogen, while OBzl protects the side hydroxyl group Gin or Arg. Phenolic hydroxyl Tug protects-, em 2,6-dichlorobenzyl (DCB). At the end of the synthesis, a peptidyl-polymer 45 of the following composition is obtained: Boc-N MeTyr (X ,,) - -Ala-Asp (X3) -Ala-Ile-Phe-Thr (X.) - -Asp (X3) -Ser (X,) - Tyr (X ,,) - Arg (X.) - -Lys (X p -Val-Leu-Ala-Gln (X,) -Leu- -Ser (X) -Ala-Arg (X) -Lys (X) -Leu-Leu-Gln (X) -Asp (X) -Ile-Nle-Asn (X) - -Arg (X) -Xj,
    where X j means DCB; X 3 - OBzl j X, - Xan; Xf - Tos-, X 2C1-Z and X g - HO- - splitter or NH-MBGasmola. Xanthine can be partially or completely removed 5 under the action of TFA used to unlock the alpha-amino protecting group. Received 6.2 g of peptide resin.
    To cleave and unlock the complex, the valuable peptidyl-polymer is treated with a mixture containing 1.5 ml of anisole, 0.5 l of methylene sulfide and 15 ml of hydrogen (HF) per 1 g of peptide-resin at (-20) C for 0.5 h and 0 ° C for another 0.5 h. After HF is removed under high pressure, the peptide remaining on the resin is alternately washed with dry diethyl ether and chloroform, and then the peptide is extracted with degassed 2 K aqueous acetic acid solution and from resin by filtration.
    The peeled off and released peptide (3.1 g) is then dissolved in 0, acetic acid solution and purified, which may include gel filtration on a Sephadex C-50.
    The resulting peptide is then further purified by preparative and semi-preparative HPLC on an HPLG pre-500 chromatograph using a 15-20f C-18 cartridge in the TEAR-2-25 system. . Own fractions are settled and then cleaned on the same cartridge in TEAR-6.5 / CH3-CH system. . Suitable fractions are settled and cleaned of salt on the same cartridge in a volatile system of 1% TFA / CH CN
    The purity on HPLC is 99.9% for 15 fractions.
    Purity on HPLC 9157-, 99.6% for 16 fractions.
    The main fraction is collected, lyophilized, and the desired product is obtained in yields of 0.95 g (22.6%), 54.83 ° (1.1% acetic acid). i
    The amino acid composition of the obtained peptide: Asp 4,14 Thr 0,98, - Ser 1,78; Gin 2.00; Ala 4.00, - Val 0 93-0.78; lie 1.77, - Leu 3.96; Nle 0.96; Tyr 0.96 Phe 0.86; Lys 1.80; Arg 2.96. .
    Example 2. Peptide Synthesis: G MeTug, Lys 8, Asn "7-hG12F (1-20) NH2, of the formula:
     N MeTyr-Ala-Asp-Ala-Ile-Phe-Tyr- -Lys-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln- -Leu-Se r-Ala-Arg-Ly s-Leu-Leu -Gln-Asp- -Ile-Nle-Asn-ArgNHj.
    This peptide is synthesized under the conditions of example 1 using the same protective groups, solvents and activating agents through the formation of a peptide polymer.
    598881 6
    The peptidyl polymer (4.6 g) is treated with HF in the presence of p-cresol, during the cleavage rate
     the culture is maintained at 0 s for 1 h. The cleaved peptide is lyophilized to obtain 2.6 g peptide. The resulting product is purified on an HPL C prep prep chromatograph. 500, pat-0 Ron 15-20 / C-18 in the TEAR-2.25 / CHjCN system. The fractions containing the peptide are collected on the same cartridge in the TEAP-6.5 / CH3CN system. Desalting is carried out on the same cartridge in a system with volatility of 1% TFA / CH CN.
    Purity on HPLC 99.9% for 15fractions.
    Purity on HPLC 99.4% for I6 fractions.
    20 Yield 0.86 g peptide (33%) -60.55.
    (With 1.1% acetic acid). Amino acid composition: Asp 3,07; Thr 0.94; Ser 1.80; Glu 2.01; Ala 4.0; 25 Val 0.97, 0.82, He 1.76; Leu 3.93; Nle 0.97; Tyr 0.93; Phe 0.85; Lys 2.78; Arg 3.15.
    Example 3. Synthesis of peptide:
    , N1 (1-29) NH, j 30 of the formula:
    . N MeTyr-Ala-Asp-Alarlle-Phe-Thr-A-As-Ser-Tyr-Arg-Lys-Val-Leu-Gly-Gln-, -Leu-Ser-Ala-Arg-DLys-Leu-Leu-Gln- Asp-.-Ile-Nle-Ser-ArgNHcz.
     This peptide is synthesized under the conditions of Example 1. The resulting intermediate product is peptidyl polymer (1.5 g). The HF is treated in the presence of p-cresol, and the temperature is kept at 0 ° C for about 40 hours during 40 ° C.
    The peptide is obtained in an amount of 0.9 g. It is purified on an HPLC chromatograph at 500 using a 45-20 C-18 Vydac packing in the system.
    TEAP / CHjCN. The fractions containing the target product, defend and desalted on the same gasket in the system 1% TFA / CH jCN.
    50 Purity on HPLC, 7% for 15 fractions, virus 0.061 g (6.1%), WUi) –53.31 (C 1, 1% acetic acid, acid). .
    A fnl acid composition: Asp 2.98; 5 Thr 0.89; Ser 2.84, Gin 2.09-, Gly 1.00 ,; Ala 2.89; Val 0.88-CH, Tyr 0.98; He 1.76; Leu 4.10; Nle 1.22; Tyr 0.97; Phe 0.85-, Lys 1.91; Arg 3.01.
    7
    Conducted biological tested obtained proposed method peptides.
    A comparison was made with the synthetic derivative of the human insulin release factor pGRF / 1-40 in in vitro experiments. When conducting tests, cultures containing rat pituitary cells were used, preassigned for 3-4 hours prior to testing. Such cell cultures are optimal for determining the secretion of growth hormone and are used in a comparative test using the general method of Val.
    The incubation with the test substance is carried out for 3-4 hours, after which an aliquot of the amount of the culture medium is isolated and purified to determine their content in the immunoreactive growth hormone (irGH) using a traditional radioimmunoassay.
    The table shows the obtained comparative test data of equimolar concentrations.



    In addition to in vitro experiments conducted to determine the secretion of growth hormone, in in vivo experiments, these synthetic peptides were administered intravenously to male rats anesthetized with urethane. They have been found to suppress spontaneous secretion of growth hormone without interfering with the reaction to exogenous GRF. Blood samples are taken immediately before administration and 10, 30 and 60 minutes after these peptides, and blood growth hormone levels are measured by radioimmunoassay. Test data obtained
    to

    of these synthetic peptides in vivo — each of them exhibits a higher biological activity than the synthetic peptide pRRF (1-40) -OH. The proposed growth hormone secretion factor (GRF) analogs have a much longer duration that confirmed by blood levels of pituitary growth hormone when measured both after 30 and 60 minutes after IV injections. Sci5
    0
    five
    five
    500 ng to 50 µg of these peptides per kg of body weight is effective for stimulating the growth hormone section.
    The tests carried out showed that the peptides obtained by the proposed method, related, like the analog - hGRF (1-40) OH, to low-toxic compounds, have a higher (1.7-5.5 times) ability to accelerate the release growth hormone under the action of the pituitary gland in in vitro experiments. In vivo tests have shown that these compounds exhibit a higher biological activity compared to the synthetic peptide hGRF (1-40) OH. In addition, they have a longer duration of action and are more accessible, since they have a chain of 11 amino acid residues shorter.
    权利要求:
    Claims (1)
    [1]
    Invention Formula
    The method of producing peptides of the general formula
    N MeTyr-Ala-Asp-Ala-Ile-Phe-Thr- -R j-Ser-Tjrr-Arg-Lys-Val-Leu-R j-Gln- -Leu-Ser-Ala-Arg-Rj-Leu-Leu -Gln-Asp- -Ile-Nle-R, g-ArgNHj., Where Rg is Lys, Asps R, is Gly, Ala
    Rj, Lys, DLys R.-Asn-Ser, characterized in that the corresponding C-terminal protected amino acid Boc-Arg-Tos is bound to the carrier polymer of MBHA, amino-0. the shield group is cleaved off and conducted. gradual increase of the peptide chain-: pi in accordance with the target peptide to form a peptidyl polymer of the general formula
    5 X, - М МеТугСХ) -Аla-Asp (Хз) -
    -A1a-11e-Pye-Thbg- (X4) -Y8 (Xs t) j-Ser (X4) -Tyr (X2) -Arg (X {) - Lys (X7) -Val- -Leu-R-, j -Gln (Xj) -Leu-Ser (X) -Ala- ..
    0
    five
    -Arg (X t).) - Leu-Leu-Gln (X,) -A9p (xp-Ile-Nle-Rj (X, or X,) - -Arg (X:) - X ,.
    where X is hydrogen or Bocj Xj is hydrogen or DCB; Xg is hydrogen or OBzlj 4 is hydrogen or Bzl Xj is hydrogen or Hap Xt is hydrogen or Tos; X is hydrogen or 2-Cl-Z; - Xj resin carrier,
    1598881
    ten
    followed by cleavage of the protecting groups and the peptide from the carrier resin using trifluoroacetic acid in dichloromethane and / or by using an HF absorber, preferably anisole or methyl ethyl sulfide, or their mixture at 0 ... (- 20) ° C, the reaction mixture is dissolved in a suitable solvent, preferably acetic acid, and the target product ch. t and isolated as base.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU1435157A3|1988-10-30|Method of producing peptides
    SU1530097A3|1989-12-15|Method of producing peptides
    CA1243303A|1988-10-18|Peptides antigonistic to corticotropin releasingfactor
    SU1598881A3|1990-10-07|Method of producing peptides
    IL98638A|1995-07-31|Human growth hormone releasing factor analogs, their preparation and pharmaceutical compositions containing them
    AU598507B2|1990-06-28|Peptides with vasorelaxant, natriuretic and diuretic effects, a process for their preparation, agents containing them, and their use
    IE840062L|1984-07-13|Peptides
    EP0352014A2|1990-01-24|Cyclic GRF analogs
    HU199508B|1990-02-28|Process for producing grf analogues and pharmaceutical compositions comprising same as active ingredient
    US4784987A|1988-11-15|GRF analogs VI
    CA2351665C|2008-09-02|Antagonistic analogs of gh-rh inhibiting igf-i and -ii
    FI94356B|1995-05-15|A process for preparing a synthetic peptide analog of a pharmaceutically acceptable growth hormone releasing factor or a non-toxic salt thereof
    CA1243301A|1988-10-18|Crf and analogs
    CA1304193C|1992-06-23|Grf analogs v
    CA1340964C|2000-04-18|Crf analogs
    FI94421C|1995-09-11|A method for preparing therapeutically useful peptides
    AU593973B2|1990-02-22|Grf analogs v
    CS276972B6|1992-11-18|Peptides, process of their preparation and pharmaceutical containing thereof
    IE892496A1|1991-02-13|Ghrh analogs
    同族专利:
    公开号 | 公开日
    PT87529A|1989-05-31|
    JP2758901B2|1998-05-28|
    FI89499B|1993-06-30|
    KR880013974A|1988-12-22|
    NO882184L|1988-11-23|
    FI882305A0|1988-05-17|
    DK280088D0|1988-05-20|
    FI882305A|1988-11-23|
    HUT46932A|1988-12-28|
    DK280088A|1988-11-23|
    PT87529B|1992-09-30|
    CA1312704C|1993-01-12|
    IL86166D0|1988-11-15|
    EP0292334A3|1990-06-27|
    FI89499C|1993-10-11|
    EP0292334A2|1988-11-23|
    ZA882832B|1988-11-11|
    AU1647788A|1988-11-24|
    NO882184D0|1988-05-19|
    KR0143913B1|1998-07-01|
    JPS649999A|1989-01-13|
    US5002931A|1991-03-26|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    US4518586A|1983-01-13|1985-05-21|The Salk Institute For Biological Studies|GRF Analogs III|
    US4528190A|1983-10-25|1985-07-09|The Salk Institute For Biological Studies|GRF Analogs IV|
    US4595676A|1983-04-26|1986-06-17|The Salk Institute For Biological Studies|Rat hypothalamic GRF|
    AU575843B2|1983-08-10|1988-08-11|The Administrators Of The Tulane Eductional Fund|Growth hormone releasing peptides|
    US4626523A|1983-09-13|1986-12-02|The Salk Institute For Biological Studies|GRF analogs II|
    CA1271600A|1985-01-07|1990-07-10|David Howard Coy|Growth hormone-releasing peptides and method oftreating mammals therewith|
    US4689318A|1985-08-29|1987-08-25|The Salk Institute For Biological Studies|GRF analogs|
    US4784987A|1987-01-13|1988-11-15|The Salk Institute For Biological Studies|GRF analogs VI|
    US4801456A|1987-07-09|1989-01-31|International Minerals & Chemical Corp.|Growth hormone-releasing factor analogs|US4734399A|1985-08-06|1988-03-29|Hoffmann-La Roche Inc.|Growth hormone releasing factor analogs|
    US5098995A|1987-05-22|1992-03-24|The Salk Institute For Biological Studies|GRF Analogs VIIA|
    DE3850015T2|1987-09-18|1994-10-20|Hoffmann La Roche|Cyclic GRF analogues.|
    EP0457786A1|1989-01-27|1991-11-27|The Upjohn Company|Stabilized, potent grf analogs|
    AU656144B2|1990-06-29|1995-01-27|F. Hoffmann-La Roche Ag|Histidine substituted growth hormone releasing factor analogs|
    DE69108192T2|1990-12-10|1995-07-20|Hoffmann La Roche|Process for the enzymatic production of GRFNH2.|
    JPH05507939A|1991-04-09|1993-11-11|
    US5262519A|1991-05-15|1993-11-16|The Salk Institute For Biological Studies|GRF analogs XI|
    CA2158782C|1994-09-23|2010-01-12|Pierrette Gaudreau|Marker for growth hormone-releasing factor receptors|
    EP0820296A4|1995-04-14|1999-06-30|Univ Tulane|Analogs of growth hormone-releasing factor|
    US7963352B2|2003-08-18|2011-06-21|Engineering RecreationLimited|Powered unicycle|
    US8800697B2|2009-09-01|2014-08-12|Ryno Motors, Inc.|Electric-powered self-balancing unicycle with steering linkage between handlebars and wheel forks|
    WO2014031904A2|2012-08-22|2014-02-27|Ryno Motors, Inc.|Electric-powered self-balancing unicycle|
    USD739307S1|2013-04-30|2015-09-22|Ryno Motors, Inc.|One-wheeled vehicle|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    US07/053,235|US5002931A|1987-05-22|1987-05-22|GRF analogs VII|
    [返回顶部]